Category: Therapeutics

JPM Meeting Notes – InVivo Therapeutics (NVIV)

My meeting with InVivo Therapeutics (NVIV) was rather boring. We talked about the weather and Boston sports teams – not much to report. Just kidding! Obviously, enrollment was a primary topic of discussion. Management continues to believe that the pace will accelerate in the coming weeks and that full enrollment is probable by the end…

Here’s Why Revive Will Close The Valuation Gap With Peers

Revive Therapeutics (TSXV: RVV) (RVVTF) Looks Significant Undervalued Valuing small and micro-cap biopharma companies is a difficult task. Most have no revenues, let alone earnings where valuation multiples can be applied. And even when revenues or earnings do exist, the market can be fickle on what specific multiples to apply. Discounted cash flow seems to be…

Interview with InVivo Therapeutics Chairman & CEO – Mark Perrin

InVivo Therapeutics (NASDAQ: NVIV) is biomaterial and medical device company focused on the treatment of spinal cord injuries. The company is developing a Neuro-Spinal Scaffold™ (NSS), a biocompatible polylactic-co-glycolic acid (PGLA) and poly-L-lysine (PLL) polymer scaffold that is designed for implantation at the site of the injury. The NSS provides structural support to the spared spinal tissue…

How I Get To $21 Per Share For InVivo Therapeutics

Earlier this week, InVivo Therapeutics (NASDAQ: NVIV) announced that the sixth-implanted patient in the INSPIRE clinical study improved from complete AIS-A spinal cord injury to an incomplete AIS-B spinal cord injury. This is the fourth patient to show improvement from the INSPIRE trial, equating to two-thirds of the first six patients enrolled in the study….